| Name | Title | Contact Details |
|---|
Atlas Copco Group enables technology that transforms the future. We innovate to develop products, services and solutions that are key to our customers success. Our four business areas offer compressed air and vacuum solutions, energy solutions, dewatering and industrial pumps, industrial power tools and assembly and machine vision solutions. In 2023, the Group had revenues of BSEK 173, and at year end about 53 000 employees.
Russell Reynolds Associates (RRA) is a global leadership advisory and executive search firm founded in 1969 in New York City. Initially focused on financial services, RRA has expanded its expertise to various industries, including healthcare, consumer goods, technology, and industrial sectors. With 47 offices worldwide, the firm specializes in identifying and developing transformational leaders for public, private, and non-profit organizations. RRA offers a range of services, including executive search for C-suite and board roles, leadership advisory for succession planning and team effectiveness, and board advisory for governance and director recruitment. The firm utilizes proprietary assessment tools, such as the Leadership Span Assessment, to evaluate leadership capabilities. RRA serves a diverse clientele, including Fortune 500 companies and non-profits, and emphasizes a high-touch approach to address challenges like sustainability and digital transformation. With over 470 consultants across 26+ countries, RRA maintains a strong international presence and adapts to evolving leadership demands.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.